AbCellera Biologics (NASDAQ: ABCL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.330 | 0.540 | 0.2100 | ||||
REV | 194.670M | 316.581M | 121.911M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of AbCellera Biologics (NASDAQ: ABCL) through any online brokerage.
There are no as such competitors for AbCellera Biologics.
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Piper Sandler on Wednesday, May 11, 2022. The analyst firm set a price target for 21.00 expecting ABCL to rise to within 12 months (a possible 173.79% upside). 7 analyst firms have reported ratings in the last year.
The stock price for AbCellera Biologics (NASDAQ: ABCL) is $7.67 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for AbCellera Biologics.
AbCellera Biologics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for AbCellera Biologics.
AbCellera Biologics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.